Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era

Citation
K. Sakata et al., Supratentorial astrocytomas and oligodendrogliomas treated in the MRI era, JPN J CLIN, 31(6), 2001, pp. 240-245
Citations number
22
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
ISSN journal
0368-2811 → ACNP
Volume
31
Issue
6
Year of publication
2001
Pages
240 - 245
Database
ISI
SICI code
0368-2811(200106)31:6<240:SAAOTI>2.0.ZU;2-S
Abstract
Background: There is at present no consensus on the policy for the treatmen t of patients with low-grade gliomas (LGGs). Methods: This report is a retrospective mufti-institutional study of 100 pa tients (ages 16-65 years) with astrocytoma (grade II), oligodendroglioma, a naplastic oligodendroglioma and anaplastic oligoastrocytoma of the supraten torial areas which were treated with surgery and postoperative radiotherapy at five university hospitals in northern Japan between 1990 and 1997 when MRI was routinely used to determine the target volume. Most patients were i rradiated with 50-60 Gy. The target volume usually covered the areas with T 2 prolongation of MRI with a margin of 2 cm. Results: The disease-specific 5-year survival rate was 87.4% for patients w ith oligodendroglioma and 75.3% for patients with astrocytoma. Survival for patients with astrocytoma in the MRI era appears to be improved compared w ith historical controls in the literature. Patients with astrocytoma aged 4 0 years and under had a significantly better disease-specific survival rate than those over 40 years (P < 0.05) and patients with oligodendroglioma an d oligoastrocytoma showed a similar tendency. Patients with astrocytoma who had over 50% of their tumor removed had a significantly better survival ra te than those who had less than 50% removed (P < 0.05). Chemotherapy appear ed to improve the disease-specific survival rate of patients with oligodend roglioma but not that of patients with astrocytoma. Conclusion: Oligodendroglioma has a more protracted course of disease progr ession than astrocytoma. This particular feature and the sensitivity of LGG s to chemotherapy as well as their relevant prognostic factors, such as age , histopathology and amount of tumor removal, should be taken into account before any decision on treatment methods for LGGs is made.